| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/08/2009 | EP2045248A1 Method for preventing coloration of catechins and dentifrice composition |
| 04/08/2009 | EP2045247A1 Compounds for the inhibition of histone deacetylase |
| 04/08/2009 | EP2045246A1 Derivatives of benzo[d] isothiazoles as histone deacetylase inhibitors |
| 04/08/2009 | EP2045245A1 Inreversible protein tyrosine kinases inhibitors and the preparation methods and uses thereof |
| 04/08/2009 | EP2045244A1 Novel crystal of substituted phenylalkanoic acid and production process |
| 04/08/2009 | EP2045243A1 Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof |
| 04/08/2009 | EP2045242A1 Heterocyclic compounds having inhibitory activity against HIV integrase |
| 04/08/2009 | EP2045241A1 Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists |
| 04/08/2009 | EP2045239A1 Novel derivatives of phthalimide as histone deacetylase inhibitors |
| 04/08/2009 | EP2045237A1 Pyrrole compounds as inhibitors of mycrobacteria, synthesis thereof and intermediates thereto |
| 04/08/2009 | EP2045234A1 New optical active phenylethanol amines and preparing method thereof |
| 04/08/2009 | EP2044959A1 In-situ gelling drug delivery system |
| 04/08/2009 | EP2044958A2 Pharmaceutical composition for treating arteriosclerosis |
| 04/08/2009 | EP2044957A1 Treatment agent for inflammatory bowel disease |
| 04/08/2009 | EP2044955A2 Methods for detecting and inhibiting angiogenesis |
| 04/08/2009 | EP2044954A1 Treatment of fungal infections |
| 04/08/2009 | EP2044945A1 Immunomodulating agent |
| 04/08/2009 | EP2044944A1 Nootropic medicinal agent |
| 04/08/2009 | EP2044943A1 Pharmaceutical compositions comprising esterified estrogens and methyltestosterone and method of using the same |
| 04/08/2009 | EP2044942A1 Pharmaceutical preparation for continuous hormonal treatment over a period of 21-28 days comprising two ethinylestradio or estradio and drospirenone compositions |
| 04/08/2009 | EP2044941A1 Multiple-phase formulation of drospirenone and estradiol as a contraceptive |
| 04/08/2009 | EP2044940A2 Methods of treating patients suffering from movement disorders |
| 04/08/2009 | EP2044939A1 Therapeutic agent for liver fibrosis |
| 04/08/2009 | EP2044938A2 Radioprotectors |
| 04/08/2009 | EP2044937A1 ANALGESIC 5, 9 - METHANOCYCLOOCTA (b) PYRIDIN - 2 (1H) - ONE DERIVATIVES, THEIR PREPARATION METHOD AND USE |
| 04/08/2009 | EP2044936A1 Vitamin E Supplementation for enhancing immune response to Tetanus Toxoid |
| 04/08/2009 | EP2044935A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases |
| 04/08/2009 | EP2044933A1 Multi particulate matrix system containing galantamine |
| 04/08/2009 | EP2044929A1 Oral fast distintegrating tablets |
| 04/08/2009 | EP2044853A1 Nutriment for use for accelarated physiological performance enhancement |
| 04/08/2009 | EP2044849A1 Process for the manufacure of an amla composition |
| 04/08/2009 | EP2044208A1 Production of ultrapure epa and polar lipids from largely heterotrophic culture |
| 04/08/2009 | EP2044200A1 Uses and compositions comprising mirnas |
| 04/08/2009 | EP2044199A2 Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| 04/08/2009 | EP2044100A2 Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| 04/08/2009 | EP2044099A2 Process for the preparation of s-fluoromethyl-6 ,9 -difluoro-11 -hydroxy-16 -methyl-17 -propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates |
| 04/08/2009 | EP2044091A2 Compounds for the treatment of periodontal disease |
| 04/08/2009 | EP2044086A2 Thiazolopyrimidine modulators of trpv1 |
| 04/08/2009 | EP2044085A2 Penem prodrugs |
| 04/08/2009 | EP2044084A2 Mtki quinazoline derivatives |
| 04/08/2009 | EP2044083A1 Antiviral agents |
| 04/08/2009 | EP2044080A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044079A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044078A1 Camptothecin derivatives with antitumor activity |
| 04/08/2009 | EP2044075A1 Furo [3, 2-b] pyrrol derivatives |
| 04/08/2009 | EP2044073A1 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
| 04/08/2009 | EP2044072A1 Amino-imidazolones and their use as a medicament for treating cognitive impairment, alzheimer disease, neurodegeneration and dementia |
| 04/08/2009 | EP2044071A1 OOXO-SUBSTITUTED IMIDAZO[1,2b]PYRIDAZINES, PRODUCTION AND USE THEREOF AS DRUGS |
| 04/08/2009 | EP2044070A1 Purine derivatives as a2a agonists |
| 04/08/2009 | EP2044066A2 Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide |
| 04/08/2009 | EP2044065A2 Compounds and compositions as hedgehog pathway modulators |
| 04/08/2009 | EP2044063A1 Pyrimidine derivatives useful in the treatment of cancer |
| 04/08/2009 | EP2044062A1 Indole compounds |
| 04/08/2009 | EP2044061A2 Benzothiophene inhibitors of rho kinase |
| 04/08/2009 | EP2044059A1 2,5-disubstituted piperidines |
| 04/08/2009 | EP2044058A1 Chemical compounds |
| 04/08/2009 | EP2044057A2 Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use |
| 04/08/2009 | EP2044056A1 Pyrimidine derivatives as alk-5 inhibitors |
| 04/08/2009 | EP2044054A2 Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity |
| 04/08/2009 | EP2044053A2 Urea compounds useful in the treatment of cancer |
| 04/08/2009 | EP2044050A1 New pyridine analogues |
| 04/08/2009 | EP2044049A2 Process for the preparation of enantiomerically pure salts of n-methyl- 3 -( 1-naph-thaleneoxy)- 3 - (-2-thienyl) propanamine |
| 04/08/2009 | EP2044047A1 Naphthofuranone derivatives as specific inhibitors of thymidylate synthases |
| 04/08/2009 | EP2044046A2 Substituted n-acyl homoserine lactones |
| 04/08/2009 | EP2044043A1 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| 04/08/2009 | EP2044042A2 Polymorphic forms of { 2-methyl-4- [4-methyl-2- (trifluoromethylphenyl) thiazol-5-methylthiol phenoxy}-acetic acid |
| 04/08/2009 | EP2044041A2 Isothiazolidines useful in the treatment of ocular hypertensive conditions |
| 04/08/2009 | EP2044040A2 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents |
| 04/08/2009 | EP2044038A2 Novel piperazines, pharmaceutical compositions and methods of use thereof |
| 04/08/2009 | EP2044036A1 [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors |
| 04/08/2009 | EP2044034A1 Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1) |
| 04/08/2009 | EP2044032A2 Novel inhibitors of hepatitis c virus replication |
| 04/08/2009 | EP2044031A1 2-(heteroaryl) alkyl indazole 6-phenyl and thienyl methyl amide as thrombin inhibitors |
| 04/08/2009 | EP2044029A1 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| 04/08/2009 | EP2044028A2 Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif) |
| 04/08/2009 | EP2044027A2 Fused bicyclic compounds interacting with the histamine h4 receptor |
| 04/08/2009 | EP2044026A1 Method of treatment of glioma brain tumour |
| 04/08/2009 | EP2044025A1 Quinolinone derivatives and their pharmaceutical compositions |
| 04/08/2009 | EP2044024A1 New pyridine analogues |
| 04/08/2009 | EP2044023A1 Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| 04/08/2009 | EP2044020A1 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| 04/08/2009 | EP2044019A1 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
| 04/08/2009 | EP2044018A1 Substituted n-bicyclicalkyl bicyclic carboxyamide compounds |
| 04/08/2009 | EP2044016A2 4-heteroaryl-substituted 1-aminocyclohexane-1-and cyclohexene-1-derivatives having effects on the opiod receptor system |
| 04/08/2009 | EP2044004A2 Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity |
| 04/08/2009 | EP2043744A2 Chemical compounds |
| 04/08/2009 | EP2043665A2 Composition for the enterosorption and management of toxins comprising a calcium aluminosilcilate clay |
| 04/08/2009 | EP2043662A2 Methods and compositions for treating disease |
| 04/08/2009 | EP2043661A1 Use of tylvalosin as antiviral agent |
| 04/08/2009 | EP2043660A2 Composition having effect of treating, preventing, or improving diabetes or diabetic complication and drink comprising the same |
| 04/08/2009 | EP2043659A1 Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent |
| 04/08/2009 | EP2043658A2 Antiviral phosphinate compounds |
| 04/08/2009 | EP2043657A2 Use of stilbene derivatives for treatment and prevention of aquatic mold infections |
| 04/08/2009 | EP2043656A2 New medical use of triazine derivatives |
| 04/08/2009 | EP2043655A2 Purine and deazapurine derivatives as pharmaceutical compounds |
| 04/08/2009 | EP2043654A2 Thienopyrimidines useful as modulators of ion channels |
| 04/08/2009 | EP2043653A2 Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| 04/08/2009 | EP2043652A2 Use of fosfluridine tidoxil (ft) for the treatment of intraepithelial proliferative diseases |
| 04/08/2009 | EP2043651A2 Methods of using igf1r and abl kinase modulators |
| 04/08/2009 | EP2043650A2 Treatment for demyelinating disease |